Truist Financial Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price hoisted by equities research analysts at Truist Financial from $490.00 to $525.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the pharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 6.69% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective for the company in a research note on Tuesday, January 6th. HC Wainwright boosted their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore increased their target price on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Bank of America raised their target price on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Royal Bank Of Canada dropped their price target on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research report on Friday, February 13th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $553.36.

Vertex Pharmaceuticals Trading Down 1.4%

VRTX stock traded down $7.09 during mid-day trading on Wednesday, reaching $492.08. 572,023 shares of the stock traded hands, compared to its average volume of 1,490,138. Vertex Pharmaceuticals has a 52-week low of $362.50 and a 52-week high of $519.68. The company has a market cap of $125.00 billion, a P/E ratio of 32.09 and a beta of 0.31. The stock’s fifty day moving average is $468.41 and its 200-day moving average is $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. During the same period last year, the business earned $3.98 earnings per share. The business’s revenue was up 9.5% on a year-over-year basis. Equities research analysts expect that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Amit Sachdev sold 1,846 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $897,802.10. Following the transaction, the executive vice president directly owned 55,570 shares of the company’s stock, valued at approximately $27,026,469.50. This represents a 3.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Duncan Mckechnie sold 4,910 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the sale, the executive vice president owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. This represents a 21.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 91,156 shares of company stock worth $42,845,497. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VRTX. PeakShares LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $1,017,000. Corient Private Wealth LLC raised its position in Vertex Pharmaceuticals by 0.8% during the fourth quarter. Corient Private Wealth LLC now owns 102,570 shares of the pharmaceutical company’s stock valued at $46,510,000 after acquiring an additional 839 shares in the last quarter. Mengis Capital Management Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $227,000. Rehmann Capital Advisory Group lifted its stake in Vertex Pharmaceuticals by 3.3% in the fourth quarter. Rehmann Capital Advisory Group now owns 1,937 shares of the pharmaceutical company’s stock valued at $879,000 after acquiring an additional 61 shares during the last quarter. Finally, SHP Wealth Management bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth approximately $220,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 3 interim results — A pre-specified Week‑36 analysis of the RAINIER trial met its primary and all secondary endpoints; povetacicept produced large reductions in proteinuria, supporting its potential as a new treatment for IgA nephropathy and strengthening Vertex’s kidney-disease expansion strategy. BusinessWire: Vertex announces positive RAINIER interim results
• Positive Sentiment: Strong efficacy details amplified optimism — Interim data showed a substantial (~50%+) reduction in proteinuria in trial patients, increasing hopes for a rapid regulatory pathway and meaningful commercial upside if approved. Zacks: VRTX gains on upbeat interim data
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Jefferies and others) raised targets and reiterated buys, pushing consensus street optimism and providing fresh institutional support. Benzinga: analyst price-target moves
• Positive Sentiment: Market reaction and visibility — Media coverage and late-session trading lifted VRTX into a leadership position on major indices as investors reprice Vertex for potential kidney-disease revenue beyond its CF franchise. Investopedia: Vertex leads S&P move after trial results
• Neutral Sentiment: Index/sector positioning — Reports note rising biotech focus within Nasdaq indices, which may increase passive and active flows into biotech names including Vertex but is less specific to company fundamentals. Kalkine: biotech focus rises in Nasdaq index
• Neutral Sentiment: Investor events and presentations — Vertex presented at industry conferences (Leerink transcript available); useful for incremental detail but not the primary price driver this week. Seeking Alpha: Leerink presentation transcript
• Negative Sentiment: Near-term caution on fundamentals/estimates — Some commentary warns that recent gains are momentum-driven and that earnings/estimate revisions or execution risks (commercial launch, pricing, competition, regulatory timing) could limit how durable the rally is. Elevated volume increases volatility risk. Zacks: will this strength last?

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.